Phio Pharmaceuticals Inc. (NASDAQ: PHIO) stock gains by 13.96% in the current market trading session. Phio Pharmaceuticals Corp. is a biotechnology business working on the next generation of immuno-oncology medicines using their INTASYSL (self-delivering RNAi) therapeutic system. The objective is to generate INTASYL therapeutic chemicals that can be used to weaponize immune effector cells and defeat tumour immune evasion.
PHIO stock’ Significant Development
Phio Pharmaceuticals released the findings of a new research showing that local treatment in vivo with INTASYL can cure tumours and develop long-lasting, tumor-specific systemic tumour immunity. These findings, which were published at the European Society of Medical Oncology (ESMO) Congress 2021, demonstrate the INTASYL technology’s promise in direct therapeutic applications.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In a preclinical in vivo hepatocellular carcinoma model, the research was conducted to demonstrate the synergistic effect of co-targeting PD-1 and BRD4 using one INTASYL formulation (PH-3861). The findings demonstrate that when animals were given low doses of PH-3861, such as levels that were not optimal for monotherapy, up to 83 percent of them exhibited a full response. Furthermore, this treatment elicited a long-lasting and targeted anti-tumor immune response that did not require subsequent treatment.
Furthermore,
Subcutaneous Hepa1-6 tumours in mice were cured with a murine form of dual targeting INTASYL PH-3861 (mPH-3861) by local injection to the tumour at low dosages that are inappropriate for a single drug targeting either PD-1 or BRD4 alone, according to the findings reported today. Mice that were completely cured of tumours with mPH-3861 were re-challenged 2.5 months later by implanting hepatoma cancer cells in a different site than the previous tumor challenge. All of the re challenged mice that had previously been cured by mPH-3861 were cured without the need for further therapy, but tumours in the control group developed slowly as expected. These findings reveal that mPH-3861 therapy induces a long-lasting and systemic anti-tumor immune response that can stop tumour growth.
